Results 201 to 210 of about 63,671 (294)

A CASE OF THYMOMA WITH MYASTHENIA GRAVIS AND PURE RED CELL APLASIA TREATED WITH THYMECTOMY AND AZATHIOPRINE

open access: bronze, 1978
S Arimori   +8 more
openalex   +2 more sources

Clinical characteristics and treatment outcomes of linear IgA bullous dermatosis

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Linear immunoglobulin A (IgA) bullous dermatosis (LABD), also referred to as chronic bullous disease of childhood (CBDC), is characterized by the linear deposition of IgA antibodies within the dermal‐epidermal junction. While dapsone is typically recommended, alternative modalities may be considered based on accessibility, severity, and prior ...
Kristie Mar   +7 more
wiley   +1 more source

Malignancy-associated risk factors in patients with systemic sclerosis. [PDF]

open access: yesJ Scleroderma Relat Disord
Baysal S   +7 more
europepmc   +1 more source

Anti‐neutrophil cytoplasmic antibodies associated interstitial pneumonia: A possible new clinical entity

open access: yesEuropean Journal of Clinical Investigation, EarlyView.
In a study of 101 idiopathic interstitial pneumonia (IIP) and interstitial pneumonia with autoimmune features (IPAF) patients, 21 (20.8%) were ANCA‐positive. ANCA+ patients had higher rates of NSIP, bronchiectasis, arthralgias, and elevated CRP, with 43% of p‐ANCA+ patients progressing to systemic vasculitis (SV) within 12 months (OR 26.3, p < .0001 ...
Claudia Iannone   +11 more
wiley   +1 more source

Rilzabrutinib for the Treatment of Immune Thrombocytopenia

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Advancements in the understanding of ITP pathogenesis have led to significant improvements in disease management through the use of both traditional immunosuppressive strategies and novel targeted therapies. However, a subset of patients remains refractory to treatment or achieves only transient benefits, underscoring the need for alternative ...
Caterina Labanca   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy